ReviewCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025
Navigating the Uncertainties of Antithrombotic Therapy After Transcatheter Patent Foramen Ovale Closure: A Comprehensive Review.
Review in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antithrombotic Therapy in Percutaneous Atrial Structural Interventions.Journal of cardiovascular development and disease · 2026Review
- Symptomatic intraocular pressure dysregulation during clopidogrel exposure after patent foramen ovale closure in a patient with ocular hypertension and angle crowding: a Case Report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The patent foramen ovale (PFO), present in 25% of the population, can cause paradoxical embolism and stroke. Transcatheter PFO closure is the gold standard for recurrent embolism with significant inter-atrial shunting, with recent trials confirming its superiority in reducing ischemic stroke recurrence over medical therapy. However, device-related thrombosis remains a concern, posing risks of systemic embolism and neurological events. Optimal post-closure antithrombotic management, including the choice and duration of therapy, remains unclear. Recommendations suggest transient dual antiplatelet therapy followed by long-term single therapy, but robust evidence is lacking, especially regarding device neo-endothelization timelines. Current studies often lack long-term follow-up, leaving gaps in understanding the incidence and prevention of thrombosis. Future research is crucial to provide evidence-based guidance and refine personalized treatment strategies for better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.